GeneralResearch & Publications

Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus

By September 1, 2008September 24th, 2020No Comments


Expert Opin Pharmacother

Pedro A Velásquez-Mieyer 1 ,
Claudia P Neira

Background: Type 1 diabetes mellitus is associated with acute and long-term
complications, to which pre- and postprandial hyperglycemia are independent
contributors. The objective of this review was to evaluate evidence-based
information using biphasic insulin aspart 30 in the treatment of type 1
diabetes mellitus.
Methods: The study reviewed the Cochrane Database and scientific literature
(PubMed) published until January 2008 using the words biphasic insulin
aspart 30 insulin or premixed aspart insulin.
Conclusions: Biphasic insulin aspart 30 is similar in efficacy to biphasic human
insulin in improving hemoglobin A(1c) levels, with the advantage of a
better postprandial glucose profile.
Expert opinion: There is evidence supporting the efficacy and safety of biphasic insulin
aspart 30 insulin. However, the need for well-designed clinical trials
aimed at understanding the potential differences in safety and efficacy
between patients with type 1 and type 2 diabetes is crucial.


Interested in this research and working with us? Please contact us here.